Bexion Loogo

High Market Potential

Bexion is currently pursuing cancer treatments where there is a significant unmet need and high market potential*.

Bexion Area of Focus Unmet Need Annual Global Market Potential
DIPG – Diffuse Intrinsic Pontine Glioma Currently, there are no approved drugs for DIPG

DIPG carries a dismal prognosis, with a 2-year survival rate of <10%, making DIPG one of the most fatal pediatric malignancies.

$15 Million-Qualify for a Rare Pediatric Voucher
Glioblastoma Multiforme (GBM) GBM average survival is 16-20 months, with only 25% of glioblastoma patients surviving 2 years. $1 Billion
Colorectal Stage 4 colorectal cancer 5-year survival rate is between 11 and 14%. $10 Billion

*BXQ-350 appears to be “tumor-agnostic” suggesting treatments for other types of cancer.

About Bexion
High Market Potential
Why Invest?
The Promise of BXQ-350